据证券之星公开数据整理，近期ST中泰(002092)发布2025年一季报。截至本报告期末，公司营业总收入 67.67亿元，同比下降13.02%，归母净利润-8979.79万元，同比上升49.28%。按单季度数据看，第一季度 营业总收入67.67亿元，同比下降13.02%，第一季度归母净利润-8979.79万元，同比上升49.28%。本报告 期ST中泰盈利能力上升，毛利率同比增幅49.68%，净利率同比增幅42.37%。 证券之星价投圈财报分析工具显示：业务评价：去年的净利率为-4.26%，算上全部成本后，公司产品或 服务的附加值不高。融资分红：公司上市19年以来，累计融资总额164.01亿元，累计分红总额22.22亿 元，分红融资比为0.14。商业模式：公司业绩主要依靠营销驱动。需要仔细研究这类驱动力背后的实际 情况。 财报体检工具显示：建议关注公司现金流状况(货币资金/流动负债仅为21.71%)建议关注公司债务状况 (有息资产负债率已达31.68%) 本次财报公布的各项数据指标表现一般。其中，毛利率20.41%，同比增49.68%，净利率-1.83%，同比 增42.37%，销售费用、管理费用、财务费用总计1 ...

Financial Performance - The company reported total revenue of 80.13 million yuan for Q1 2025, a decrease of 0.48% year-on-year [1] - The net profit attributable to the parent company was 7.96 million yuan, an increase of 47.45% year-on-year [1] - The gross profit margin improved to 25.35%, up 20.67% year-on-year, while the net profit margin increased to 9.92%, up 48.38% year-on-year [1] - Total operating expenses (selling, administrative, and financial expenses) amounted to 8.58 million yuan, accounting for 10.71% of revenue, a decrease of 8.4% year-on-year [1] Balance Sheet Highlights - Cash and cash equivalents increased to 57.61 million yuan, a rise of 53.32% year-on-year [1] - Accounts receivable rose to 31.10 million yuan, with a year-on-year increase of 38.72% [1] - Interest-bearing liabilities decreased to 79.13 million yuan, down 36.44% year-on-year [1] Earnings Per Share - Earnings per share (EPS) increased to 0.03 yuan, reflecting a growth of 50.0% year-on-year [1] - The net asset per share rose to 0.26 yuan, an increase of 18.38% year-on-year [1] - Operating cash flow per share remained at 0.02 yuan, with an increase of 18.58% year-on-year [1] Business Evaluation - The company's return on invested capital (ROIC) was 6.93%, indicating average capital returns [3] - The net profit margin for the previous year was 2.54%, suggesting low added value for products or services [3] - The company has raised a total of 964 million yuan since its listing, with cumulative dividends amounting to 50.62 million yuan, resulting in a dividend-to-financing ratio of 0.05 [3] Cash Flow and Receivables - The cash flow situation is concerning, with cash and cash equivalents to current liabilities ratio at 25.71% and average operating cash flow to current liabilities at 11.2% over the past three years [3] - Accounts receivable have reached 365.68% of profit, indicating potential issues with receivables management [3]

Financial Performance - Company reported total revenue of 3.141 billion yuan for Q1 2025, an increase of 4.42% year-on-year [1] - Net profit attributable to shareholders reached 11.3683 million yuan, up 73.46% compared to the same period last year [1] - Gross margin improved to 6.14%, reflecting a year-on-year increase of 52.56%, while net margin rose to 0.18%, a significant increase of 292.04% [1] Cost and Expenses - Total selling, administrative, and financial expenses amounted to 176 million yuan, accounting for 5.6% of revenue, which is a slight increase of 1.76% year-on-year [1] - The company’s operating cash flow per share was -0.15 yuan, showing a year-on-year increase of 4.33% [1] Balance Sheet and Debt - Cash and cash equivalents decreased by 14.02% to 3.267 billion yuan [1] - Accounts receivable increased by 73.99% to 681 million yuan, indicating potential liquidity concerns [1] - Interest-bearing liabilities rose by 10.90% to 8.253 billion yuan, with a debt-to-asset ratio of 40.21% [3] Shareholder Returns - The company has cumulatively raised 4.226 billion yuan since its listing, with total dividends amounting to 699 million yuan, resulting in a dividend-to-financing ratio of 0.17 [3]

Financial Performance - The company reported a total revenue of 125 million yuan for Q1 2025, representing a year-on-year increase of 5.06% [1] - The net profit attributable to shareholders reached 14.71 million yuan, up 30.49% year-on-year [1] - The gross margin improved to 29.76%, an increase of 4.51% compared to the previous year [1] - The net margin rose to 11.86%, reflecting a year-on-year increase of 23.44% [1] - Total expenses (selling, administrative, and financial) amounted to 12.98 million yuan, accounting for 10.35% of revenue, which is a 20.64% increase year-on-year [1] Key Financial Ratios - Earnings per share (EPS) increased to 0.1 yuan, a rise of 25% year-on-year [1] - The company's return on invested capital (ROIC) was reported at 6.4%, indicating average capital returns [3] - The net profit margin for the previous year was 10.81%, suggesting average added value for products or services [3] Cash Flow and Debt Management - The company reported a negative operating cash flow of -0.03 yuan per share, which is an improvement of 82.12% year-on-year [1] - The company has a healthy cash asset position, with total cash assets reported at 243 million yuan, down 4.14% from the previous year [3] - Interest-bearing debt significantly decreased to 4.96 million yuan, a reduction of 82.71% year-on-year [1] Market Strategy and Outlook - The company expressed confidence in the domestic market's potential, emphasizing plans to balance domestic and international sales [3] - The company aims to continue expanding both domestic and international markets, focusing on consumer demand [3]

Core Viewpoint - The recent financial report of Haiprui (002399) shows a year-on-year increase in both revenue and net profit for Q1 2025, indicating stable performance despite some declines in profit margins and cash flow metrics [1]. Financial Performance - Total revenue for Q1 2025 reached 1.394 billion yuan, a 1.53% increase compared to 1.373 billion yuan in Q1 2024 [1]. - The net profit attributable to shareholders was 157 million yuan, reflecting a 1.0% increase from 155 million yuan in the same period last year [1]. - Gross margin decreased to 27.34%, down 20.74% year-on-year, while net margin slightly declined to 11.2%, a decrease of 0.51% [1]. - Total expenses (selling, administrative, and financial) amounted to 135 million yuan, representing 9.66% of revenue, a significant reduction of 45.77% year-on-year [1]. Key Financial Ratios - Earnings per share (EPS) remained stable at 0.11 yuan, with a slight increase of 0.95% year-on-year [1]. - The company's cash flow per share decreased to 0.37 yuan, down 38.21% from 0.60 yuan [1]. - The company's return on invested capital (ROIC) was reported at 4.33%, indicating weak capital returns in recent years [3]. Debt and Cash Flow Analysis - The company has a healthy cash position, with cash assets covering 87.19% of current liabilities [3]. - The interest-bearing debt decreased to 3.544 billion yuan, a reduction of 27.03% compared to the previous year [1]. - Accounts receivable increased to 1.382 billion yuan, a rise of 19.95% year-on-year, raising concerns about collection efficiency as accounts receivable to profit ratio reached 213.74% [3]. Market Dynamics - The company is closely monitoring the market for heparin active pharmaceutical ingredients (API), which are currently priced low, and is focused on maintaining its pricing structure [3].

| 持有数量(万股) 名称 | | 占总股本比例 | 增减情况(万 | | --- | --- | --- | --- | | | | (%) | 股) | | 珠海植诚投资中心(有限合伙) | 9297.68 | 9.00 | 不变 | | 珠海植远投资中心(有限合伙) | 8742.48 | 8.46 | 不变 | | 蔡小如 | 7128.40 | 6.90 | -67.68 | | 陈融圣 | 6132.91 | 5.94 | 新进 | | 百年人寿保险股份有限公司-传统保险产品 | 1417.10 | 1.37 | 不变 | | 领颐(上海)资产管理有限公司-领颐16号私募证券投 资基金 | 990.00 | 0.96 | 不变 | | 香港中央结算有限公司 | 866.33 | 0.84 | 106.69 | | 郑林峰 | 494.26 | 0.48 | 新进 | | 蔡碧琴 | 417.04 | 0.40 | -218.97 | | 黄学明 | 377.65 | 0.37 | -4.16 | | 较上个报告期退出前十大股东有 | | | | | 葛道山 | 300.06 | 0.29 | 退出 ...

Core Insights - Centene reported $46.62 billion in revenue for Q1 2025, a 15.4% year-over-year increase, with an EPS of $2.90 compared to $2.26 a year ago, exceeding Zacks Consensus Estimates for both revenue and EPS [1] - The company delivered a revenue surprise of +7.24% and an EPS surprise of +22.88% compared to analyst expectations [1] Financial Performance Metrics - Total Medical Health Benefits loss ratio was 87.1%, better than the estimated 87.9% [4] - Membership in High Acuity Medicaid stood at 1.59 million, matching analyst estimates [4] - Medicaid membership reached 12.96 million, slightly above the 12.94 million estimate [4] - SG&A Expense Ratio was 7.9%, lower than the estimated 8.4% [4] - Premium and service revenues totaled $42.49 billion, exceeding the $40.12 billion estimate, reflecting a 16.9% year-over-year increase [4] - Premium revenues were $41.71 billion, surpassing the $39.35 billion estimate, marking a 17.4% year-over-year change [4] - Service revenues were $777 million, slightly above the $768.54 million estimate, but a 3.8% decrease year-over-year [4] - Premium tax revenues were $4.13 billion, exceeding the $3.52 billion estimate, with a 1.5% year-over-year increase [4] - Commercial premium and service revenues reached $10.15 billion, significantly above the $9.04 billion estimate, representing a 30.9% year-over-year increase [4] - Medicare premium and service revenues were $8.76 billion, exceeding the $8.54 billion estimate, with a 47.6% year-over-year increase [4] - Medicaid premium and service revenues totaled $22.30 billion, above the $21.45 billion estimate, reflecting a 3.9% year-over-year increase [4] - Other premium and service revenues were $1.28 billion, exceeding the $1.22 billion estimate, with a 7.6% year-over-year increase [4] Stock Performance - Centene's shares returned +2.2% over the past month, contrasting with the Zacks S&P 500 composite's -4.8% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market [3]

Core Insights - The company reported a stable basic earnings per share of 0.0600 yuan for Q1 2025, unchanged from Q1 2024, but an improvement from a loss of 0.0500 yuan in Q1 2023 [1] - The company's total revenue for Q1 2025 was 1.3 billion yuan, representing a 22.64% increase compared to 1.06 billion yuan in Q1 2024 and a significant increase from 0.96 billion yuan in Q1 2023 [1] - Net profit for Q1 2025 was 0.09 billion yuan, up 12.5% from 0.08 billion yuan in Q1 2024, and a recovery from a loss of 0.05 billion yuan in Q1 2023 [1] - The company's return on equity (ROE) improved to 2.56% in Q1 2025 from 2.33% in Q1 2024, compared to a negative ROE of -1.62% in Q1 2023 [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 7.2072 million shares, accounting for 11.5502% of the circulating shares, with an increase of 485,300 shares compared to the previous period [1] - The largest shareholder, Gai Quan Hong, holds 2.6745 million shares, representing 4.29% of the total share capital, with no change in holdings [2] - Other notable shareholders include Shen Jinlong with 1.2632 million shares (2.03%, decreased by 17,600 shares) and Ma Hongxian with 685,900 shares (1.10%, increased by 145,300 shares) [2] Dividend Policy - The company has decided not to distribute dividends or transfer shares in the current period [3]

Financial Performance - The company reported a basic earnings per share of -0.1300 yuan for Q1 2025, an improvement of 18.75% compared to -0.1600 yuan in Q1 2024, and a significant increase from -0.2600 yuan in Q1 2023 [1] - The net profit for Q1 2025 was -0.4 billion yuan, showing a 24.53% improvement from -0.53 billion yuan in Q1 2024 and a notable increase from -0.86 billion yuan in Q1 2023 [1] - Operating revenue decreased by 5.78% to 2.77 billion yuan in Q1 2025, down from 2.94 billion yuan in Q1 2024 and 3.46 billion yuan in Q1 2023 [1] - The return on equity for Q1 2025 was -0.73%, an improvement from -0.94% in Q1 2024 and -1.55% in Q1 2023 [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 93.81 million shares, accounting for 54.06% of the circulating shares, which is a decrease of 12.32 million shares from the previous period [2] - The largest shareholder, Zhangjiagang Huahui Enterprise Management Service Department, holds 19.00 million shares, representing 10.95% of the total share capital, with a decrease of 1.65 million shares [3] - The second-largest shareholder, Zhangjiagang Yirui Enterprise Consulting Service Department, holds 18.16 million shares, accounting for 10.47% of the total, with a reduction of 1.91 million shares [3] Dividend Distribution - The company has announced that there will be no distribution or transfer of dividends this time [4]

Core Insights - Seacoast Banking (SBCF) reported revenue of $140.7 million for Q1 2025, reflecting a 12% increase year-over-year, and EPS of $0.38, up from $0.31 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate of $136.9 million by 2.77%, while the EPS fell short of the consensus estimate of $0.40 by 5% [1] Financial Performance Metrics - Net Interest Margin was reported at 3.5%, surpassing the average estimate of 3.4% from three analysts [4] - Efficiency Ratio stood at 60.3%, better than the average estimate of 63.1% based on three analysts [4] - Total Net Charge-offs to Average Loans was 0.3%, compared to the estimated 0.2% by two analysts [4] - Total nonperforming loans amounted to $71.02 million, significantly lower than the average estimate of $99.10 million [4] - Total nonperforming assets were reported at $78.19 million, compared to the average estimate of $105.73 million [4] - Average Balance of Total Earning Assets was $13.83 billion, slightly above the estimated $13.79 billion [4] - Total noninterest income was $22.18 million, slightly below the average estimate of $22.45 million [4] - Net interest income (FTE) was $118.86 million, exceeding the average estimate of $115.96 million [4] - Net interest income was reported at $118.52 million, compared to the average estimate of $115.64 million [4] Stock Performance - Shares of Seacoast Banking have returned -9.6% over the past month, underperforming the Zacks S&P 500 composite's -5.1% change [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]